Disease Landscape and Forecast Insights

Payers play a significant role in defining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

Celltrion’s Herzuma was the first biosimilar of Roche’s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, three additional trastuzumab biosimilars…

MARKET OUTLOOK Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has globally the highest number of RA patients, and the Chinese…

MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen), and…

With the launch of four adalimumab biosimilars into the European market in October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), and Hyrimoz (Sandoz)—competition within the already…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

The wet AMD market is dominated by three therapies—Roche / Genentech / Novartis’s Lucentis, approved for wet AMD, Roche / Genentech / Chugai’s Avastin, approved for cancer but commonly…

Market OutlookClinical pathways, which establish optimal treatment protocols for specific patient populations based on the best evidence, have become increasingly prevalent in the treatment of…

MARKET OUTLOOK Treatment of moderate to severe Crohn’s disease (CD) typically begins with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) and progresses to more-potent…

In 2017, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology, exceeded $80 billion across the major markets (United States, EU5, and Japan…

Decision Resources Group anticipates the next ten years to be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to grow. Existing agents fail to…

With the launch of four adalimumab biosimilars into the European market in October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), and Hyrimoz (Sandoz)—competition within the already…